𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The contribution of HIV fitness to the evolution pattern of reverse transcriptase inhibitor resistance

✍ Scribed by Elijah Paintsil; Asa Margolis; Jennifer A. Collins; Louis Alexander

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
104 KB
Volume
78
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis

All currently recommended anti-retroviral therapy protocols employ reverse transcriptase inhibitors (RTIs). However, mutations within the reverse transcriptase (RT) domain can lead to resistance to these agents and treatment failure. The contribution of the fitness of drug-resistant species to the evolution of RTI resistance has not been elucidated despite its potential implications for therapeutic strategies. In this study we utilized a competitive fitness assay to assess the relative fitness of 13 drug-resistant HIV-1 mutants in the presence and absence of inhibitor. Among these mutants were thymidine analog mutations (TAMs) such as 41L/210W/215Y and 67N/70R/219Q, as well as single mutants such as 103N and 181C that confer high-level resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as nevirapine. These studies revealed that 67N/70R and 67N/70R/219Q were fitter than the 70R progenitor species, and the acquisition of 41L by 215Y substantially increased its fitness in the absence of drug. We also observed that 215Y was more fit than 70R and 67N/70R, and that 41L/215Y and 41L/210W/215Y were the most-fit species in the presence of zidovudine. Moreover, 103N was fitter than 181C without nevirapine but less fit with nevirapine. From these studies we conclude that viral fitness contributes substantially to the evolutionary pattern of TAMs suggesting that, as for protease inhibitor resistance, mutations can act in primary (increasing resistance) and secondary (increasing fitness) capacities. We also surmise that drug resistance and fitness are competing forces underlying the emergence of nevirapine resistant mutants 103N and 181C.

📜 SIMILAR VOLUMES

Emergence and genetic evolution of HIV-1
Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors
✍ Cabana, Marta; Clotet, Bonaventura; Mart�nez, Miguel-Angel 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 302 KB

The emergence of genotypic resistance in protease and reverse transcriptase (RT) gene regions was longitudinally evaluated in plasma samples from a group of 12 HIV-1-infected patients treated with different combination of antiretroviral therapies and selected on the basis of their clinical failure.

Thymidine analogue reverse transcriptase
Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure
✍ Anne-Geneviève Marcelin; Constance Delaugerre; Marc Wirden; Pedro Viegas; Anne S 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

During ZDV or d4T exposure, mutations at codons 41, 67, 70, 210, 215, and 219 can be selected and were named thymidine analogue mutations (TAMs). Some previous results suggested that different TAMs patterns could exist and that the kind of TAMs pattern could influence the virological response to som

Impact of unreported HIV-1 reverse trans
Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors
✍ A. Saracino; L. Monno; L. Scudeller; D.C. Cibelli; A. Tartaglia; G. Punzi; C. To 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB

## Abstract An extended spectrum of HIV‐1 reverse‐transcriptase (RT) mutations in HAART‐treated patients has been recently described. To verify the possible association of previously unreported RT mutations with a decrease of phenotypic susceptibility to nucleoside (NRTIs) and non‐nucleoside (NNRTI

Conformational analysis of the HIV-1 vir
Conformational analysis of the HIV-1 virus reverse transcriptase nonnucleoside inhibitors: TIBO and nevirapine
✍ Odonírio Abrahão-Júnior; Paulo G. B. D. Nascimento; Sérgio E. Galembeck 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 244 KB

## Abstract TIBO (Tetrahydro‐imidazo[4,5,1‐jk][1,4]‐benzodiazepin‐2‐one) and nevirapine (11‐cyclopropyl‐5,11‐dihydro‐4‐methyl‐6H‐dipyrido[3,2‐b:2′,3′‐e][1,4]diazepin‐6‐one) are models for two classes of nonnucleoside inhibitors of the HIV‐1 virus reverse transcriptase (NNRTI). This work presents th